The human microbiome is increasingly recognized as a key factor in immune development and disease susceptibility, especially in early life. Nasal microbiome has emerged as a critical element in upper airway health, yet its role in pediatric otorhinolar…
BackgroundGlioma is a highly heterogeneous and aggressive malignancy of the central nervous system, and reliable molecular biomarkers are urgently needed to improve prognostic stratification and guide therapeutic decision-making. The MEX3 family of RNA…
Arising from extracranial cancers, brain metastases (BrM) are the most prevalent brain malignancy in adults. Even though there are recent advances in systemic cancer therapies and immunotherapies, the prognosis for BrM remains poor, with median surviva…
BackgroundThe prognostic nutritional index (PNI), reflecting nutritional and immune-inflammatory status, has been linked to outcomes across a range of disorders. Its prognostic value in acute pancreatitis (AP) and the potential mediating role of system…
Tumor-associated macrophages (TAMs) are central regulators of the metabolic and immunological landscape of solid tumors and are increasingly recognized as key determinants of cancer-cell susceptibility to ferroptosis. Ferroptosis, an iron-dependent for…
BackgroundN6-methyladenosine (m6A), the most prevalent and reversible post-transcriptional RNA modification, is involved in the progression of various diseases. Nonetheless, the role of m6A modification in Tuberculosis (TB) pathogenesis remains unknown…
ObjectiveSkin cutaneous melanoma (SKCM) is a highly aggressive malignancy originating from melanocytes, with a continuously rising global incidence. Developing strategies for early prevention and precise treatment remains a major challenge in oncology….
Chimeric antigen receptor (CAR) cellular immunotherapy has emerged as a revolutionary modality in cancer treatment. CAR-T cell therapy has demonstrated remarkable efficacy against hematological malignancies; however, its application in solid tumors is …
Complement-mediated hemolytic uremic syndrome (CM-HUS), commonly referred to as atypical HUS, is a rare thrombotic microangiopathy caused by uncontrolled activation of the alternative complement pathway, typically triggered by a “two-hit” mechanism. It…
Combination therapy targeting the PD-1/PD-L1 and TIGIT pathways has been explored to enhance the efficacy of current immunotherapies. In this study, we investigated strategies to further potentiate the co-blockade of PD-L1 and TIGIT for cancer immunoth…
